ヒト微生物叢（ヒトマイクロバイオーム）の世界市場予測（～2027年）...市場調査レポートについてご紹介

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Covered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 19)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
3 Executive Summary (Page No. – 25)
4 Premium Insights (Page No. – 28)
4.1 Human Microbiome: Market Overview
4.2 Human Microbiome Market, By Product
4.3 Europe: Market, By Product & Application (2022)
4.4 Market, By Disease
5 Market Overview (Page No. – 32)
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increased Focus on Human Microbiome Therapy Development
5.1.1.2 Human Microbiome as A Validated Target for Drug Development
5.1.1.3 Human Microbiome for Early Disease Detection and Diagnosis
5.1.2 Restraints
5.1.2.1 Lack of Expertise and Detailed Research
5.1.2.2 Barriers in Proving the Causal Link Between Dysbiosis and Disease
5.1.3 Opportunities
5.1.3.1 Investigational New Drug Requirements for Fecal Microbiota
5.1.3.2 Increasing Collaborations
5.1.4 Challenges
5.1.4.1 Government Regulations
6 Human Microbiome Market, By Product (Page No. – 37)
6.1 Introduction
6.2 Probiotics
6.2.1 Ongoing Researches on Probiotics Promoting Its Credibility in Health Claims and Safety
6.3 Prebiotics
6.3.1 Development of Targeted Prebiotics Towards Enhancing GUT Microbiota is the Key Growth Driver for This Segment
6.4 Foods
6.4.1 Rising Awareness of Microbiota-Targeted Diets is Driving Market Growth
6.5 Medical Foods
6.5.1 Usage of Targeted Microbiome for Treating Metabolic Syndrome is Expected to Drive This Segment
6.6 Diagnostic Tests
6.6.1 Increased Consumer Awareness About Microbiome-Based Tests, Which Provide Preventative Health Insights to Drive This Segment
6.7 Drugs
6.7.1 Increasing Number of Microbiome-Based Drug Pipeline is the Key Factor Driving the Growth of This Segment
7 Human Microbiome Market, By Application (Page No. – 47)
7.1 Introduction
7.2 Therapeutics
7.2.1 Availability of Funding for Research and Growing Evidence for Effectiveness of Microbiome is Favoring Market Growth
7.3 Diagnostics
7.3.1 Increasing Focus of Biotech Companies on Life Science Research is Supporting Market Growth
8 Human Microbiome Market, By Disease (Page No. – 52)
8.1 Introduction
8.2 Infectious Diseases
8.2.1 Increasing R&D Into Targeted Anti-Bacterial Products Will Drive Market Growth
8.3 Inflammatory Diseases
8.3.1 Side-Effects of Immunosuppressants have Prompted Demand for Better Therapeutics
8.4 Endocrine & Metabolic Disorders
8.4.1 GUT Microbiota has Become A Potential Nutritional and Pharmacological Target for Obesity Management
8.5 Cancer
8.5.1 Microbiome-Based Products have Demonstrated Efficacy in the Treatment of Cancer Polyps
8.6 Other Diseases
9 Human Microbiome Research Spending Market, By Technology (Page No. – 62)
9.1 Introduction
9.2 Genomics
9.2.1 Sequencing
9.2.1.1 The Declining Cost of Next-Generation Sequencing is Driving the Growth of This Market
9.2.2 Other Genomics Technologies
9.3 Proteomics
9.3.1 Technological Advancements in Proteomics Technologies to Drive Market Growth
9.4 Metabolomics
9.4.1 Metabolomics has Several Advantages Over Genomics and Proteomics in Microbiome Research
10 Human Microbiome Market, By Region (Page No. – 70)
10.1 Introduction
10.2 Europe
10.2.1 Extended Applications for Microbiome to Therapeutic Areas to Boost the Adoption of Microbiome-Based Products in Europe
10.3 North America
10.3.1 US
10.3.1.1 Rising of Investment By Nih to Support Microbiome Research is Driving the Market Growth in the US
10.3.2 Canada
10.3.2.1 The Canadian Microbiome Initiative 2 is Supporting the Market Growth in the Country
10.4 Asia Pacific
10.4.1 Increasing Focus on Microbiome Research to Drive Market Growth
10.5 Rest of the World (RoW)
10.5.1 Increasing Incidence of Cancer to Drive the Development of Microbiome-Based Diagnostic Tools in RoW
11 Competitive Landscape (Page No. – 92)
11.1 Overview
11.2 Competitive Leadership Mapping (2018)
11.2.1 Innovators
11.2.2 Emerging Companies
11.3 Competitive Situation and Trends
11.3.1 Agreements, Collaborations, and Partnerships
11.3.2 Acquisitions and Mergers
11.3.3 Product Launches
11.3.4 Expansions
12 Company Profiles (Page No. – 97)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 Enterome Bioscience
12.2 Seres Therapeutics
12.3 4D Pharma PLC
12.4 Ubiome, Inc.
12.5 E.I. Du Pont De Nemours and Company
12.6 Synlogic
12.7 Second Genome
12.8 Vedanta Biosciences, Inc.
12.9 Ferring Pharmaceuticals
12.10 Evelo Biosciences, Inc.
12.11 Vithera Pharmaceuticals, Inc.
12.12 Biomx
12.13 LNC Therapeutics
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 122)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details